Université Paris Cité, INSERM UMR1137, IAME, Paris, France.
Institut Pasteur, Université Paris Cité, CNRS UMR6047, Bacteriophage Bacterium Host, Paris, France.
J Virol. 2024 Oct 22;98(10):e0111324. doi: 10.1128/jvi.01113-24. Epub 2024 Aug 30.
Bacteria exposed to bactericidal treatment, such as antibiotics or bacteriophages (phages), often develop resistance. While phage therapy is proposed as a solution to the antibiotic resistance crisis, the bacterial resistance emerging during phage therapy remains poorly characterized. In this study, we examined a large population of phage-resistant extra-intestinal pathogenic 536 clones that emerged from both (non-limited liquid medium) and (murine pneumonia) conditions. Genome sequencing uncovered a convergent mutational pattern in phage resistance mechanisms under both conditions, particularly targeting two cell-wall components, the K15 capsule and the lipopolysaccharide (LPS). This suggests that their identification could be predicted from assays. Phage-resistant clones exhibited a wide range of fitness according to tests, growth rate, and resistance to amoeba grazing, which could not distinguish between the K15 capsule and LPS mutants. In contrast, K15 capsule mutants retained virulence comparable to the wild-type strain, whereas LPS mutants showed significant attenuation in the murine pneumonia model. Additionally, we observed that resistance to the therapeutic phage through a nonspecific mechanism, such as capsule overproduction, did not systematically lead to co-resistance to other phages that were initially capable or incapable of infecting the wild-type strain. Our findings highlight the importance of incorporating a diverse range of phages in the design of therapeutic cocktails to target potential future phage-resistant clones effectively.
This study isolated more than 50 phage-resistant mutants from both and conditions, exposing an extra-intestinal pathogenic strain to a single virulent phage. The characterization of these clones revealed several key findings: (1) mutations occurring during phage treatment affect the same pathways as those identified ; (2) the resistance mechanisms are associated with the modification of two cell-wall components, with one involving receptor deletion (phage-specific mechanism) and the other, less frequent, involving receptor masking (phage-nonspecific mechanism); (3) an virulence assay demonstrated that the absence of the receptor abolishes virulence while masking the receptor preserves it; and (4) clones with a resistance mechanism nonspecific to a particular phage can remain susceptible to other phages. This supports the idea of incorporating diverse phages into therapeutic cocktails designed to collectively target both wild-type and phage-resistant strains, including those with resistance mechanisms nonspecific to a phage.
细菌暴露于杀菌处理(如抗生素或噬菌体(噬菌体))中时,通常会产生耐药性。虽然噬菌体疗法被提议作为解决抗生素耐药性危机的一种方法,但噬菌体治疗过程中出现的细菌耐药性仍未得到充分描述。在这项研究中,我们检查了从两种情况下(非有限液体培养基)和(鼠肺炎)中出现的大量噬菌体耐药性 536 克隆。基因组测序揭示了两种情况下噬菌体耐药机制的趋同突变模式,特别是针对两种细胞壁成分,K15 荚膜和脂多糖(LPS)。这表明它们的鉴定可以从 测定中预测。根据 测试,噬菌体抗性克隆的适应性范围很广,生长速度和对食菌的抗药性各不相同,无法区分 K15 荚膜和 LPS 突变体。相比之下,K15 荚膜突变体保留了与野生型菌株相当的毒力,而 LPS 突变体在鼠肺炎模型中表现出明显的衰减。此外,我们观察到通过非特异性机制(例如荚膜过度产生)对治疗性噬菌体的耐药性并不系统地导致对最初能够或不能感染野生型菌株的其他噬菌体的共同耐药性。我们的研究结果强调了在治疗性鸡尾酒的设计中纳入多种噬菌体的重要性,以有效地针对潜在的未来噬菌体耐药性克隆。
本研究从 和 条件下分离出超过 50 个噬菌体耐药突变体,使肠道外致病性 菌株暴露于单一毒力噬菌体。对这些克隆的表征揭示了几个关键发现:(1)噬菌体治疗过程中发生的突变影响与鉴定的相同途径; (2)耐药机制与两种细胞壁成分的修饰有关,一种涉及受体缺失(噬菌体特异性机制),另一种则不太常见,涉及受体掩蔽(噬菌体非特异性机制); (3) 毒力测定表明,受体缺失会消除毒力,而受体掩蔽则保留其毒力; (4)对特定噬菌体无特异性耐药机制的克隆仍可能对其他噬菌体敏感。这支持了将多种噬菌体纳入旨在共同针对野生型和噬菌体耐药菌株的治疗性鸡尾酒的想法,包括对噬菌体无特异性耐药机制的菌株。